# Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

> **NCT05664932** · PHASE3 · UNKNOWN · sponsor: **Guangzhou Patronus Biotech Co., Ltd.** · enrollment: 1200 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
- **BIOLOGICAL:** ZF2001

## Key facts

- **NCT ID:** NCT05664932
- **Lead sponsor:** Guangzhou Patronus Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-28
- **Primary completion:** 2023-01-18
- **Final completion:** 2023-12-31
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05664932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05664932, "Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05664932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*